This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Y-mAbs Therapeutics’s 8K filing here.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
See Also
- Five stocks we like better than Y-mAbs Therapeutics
- What is the FTSE 100 index?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 11/4 – 11/8
- Financial Services Stocks Investing
- Trump’s Return: Which Sectors Will Benefit Most?
